Utility of Restricted Mean Survival Time for Analyzing Time to Nursing Home Placement Among Patients With Dementia
Authors:
- 4 January 2021
- journal article
- letter
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 4 (1) , e2034745
Abstract
Delaying nursing home (NH) placement for patients with dementia is an important goal. The effect of a treatment for dementia on NH placement is conventionally summarized as a hazard ratio, risk difference, or median time difference. Recently, restricted mean survival time (RMST) has been proposed as an intuitive measure that summarizes treatment effect in terms of the difference in the number of event-free days.1-3 Despite its advantages over conventional measures (Table), to date, RMST has not been applied to clinical trials of dementia treatments. We assessed the utility of RMST in analyzing time to NH placement among patients with dementia using the Donepezil and Memantine in Moderate to Severe Alzheimer’s Disease (DOMINO-AD) trial as an example.4,5Keywords
This publication has 6 references indexed in Scilit:
- Applying Evidence-Based Medicine to Shared Decision Making: Value of Restricted MeanSurvival TimeThe American Journal of Medicine, 2019
- Restricted Mean Survival Time as a Measure to Interpret Clinical Trial ResultsJAMA Cardiology, 2017
- Nursing home placement in the Donepezil and Memantine in Moderate to Severe Alzheimer's Disease (DOMINO-AD) trial: secondary and post-hoc analysesThe Lancet Neurology, 2015
- Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcomeBMC Medical Research Methodology, 2013
- Donepezil and Memantine for Moderate-to-Severe Alzheimer's DiseaseNew England Journal of Medicine, 2012
- Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curvesBMC Medical Research Methodology, 2012